Manifestaciones musculoesqueléticas distales en la polimialgia reumática

Menéndez, J. Noval; Serrano, M. T. Campoamor; Mateo, F. J. Nuño; Tassa, J. Morís de la

doi:10.1016/s0014-2565(02)71086-2

Cited by 5 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such distal manifestations include peripheral arthritis, most commonly asymmetric, affecting the wrists and knees [25,26] . Differentiating these patients from those with late-onset rheumatoid arthritis (LORA) can be problematic; however, the combination of bilateral wrist synovitis, and metacarpophalangeal or proximal interphalangeal synovitis is more indicative of a diagnosis of rheumatoid arthritis over PMR [27] . Moreover, the peripheral arthritis typically associated with PMR is non-erosive and very steroid-responsive [28] .…”

Section: Clinical Diagnosismentioning

confidence: 99%

“…Additionally, US of the hip can be time-consuming, and uncomfortable for the patient, and therefore, it is not always feasible in clinical practice, somewhat limiting the real-world application of the 2012 EULAR/ACR provisional classification criteria. With advancements in imaging modalities, we are coming to appreciate the involvement of anatomical areas outside of the hips and shoulders in PMR, most notably the knees and interspinous processes [27,28,81,82] . Accordingly, one group assessed the role of US of the shoulder and knee in discriminating newly diagnosed PMR from other differential diagnoses, and found that US assessment of the tendon and ligament-related lesions in both shoulders (long head of biceps, supraspinatus or subscapularis tendon) and both knees (popliteus tendon or medial or lateral collateral ligament) increased the diagnostic accuracy of the 2012 EULAR/ ACR provisional classification criteria for PMR [83] .…”

Section: Imagingmentioning

confidence: 99%

See 1 more Smart Citation

Polymyalgia rheumatica - an up-to-date review on diagnosis and management

Harkins,

McCann,

Harrington

et al. 2024

Vessel Plus

View full text Add to dashboard Cite

Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in those over the age of 50 years. Previously it was considered to be a benign clinical syndrome characterised by subacute onset bilateral shoulder and pelvic girdle pain and stiffness, with a corresponding rise in acute phase reactants, and distinctive rapid resolution of symptoms with the instigation of moderate doses of glucocorticoids. However, over the past decade, with the advancements and, indeed, wider application of imaging modalities in PMR, we have garnered an increased understanding of the anatomic predilection of inflammation and, subsequently, disease pathogenesis. Moreover, our appreciation of the relationship between PMR and giant cell arteritis (GCA) has strengthened. Glucocorticoids have formed the cornerstone of the management of PMR for decades, with often protracted treatment durations and associated high cumulative steroid burden and adverse effects. However, we are now on the cusp of a new era in the management of PMR, with our therapeutic armamentarium expanding with the recent FDA approval of the interleukin -6 antagonist sarilumab for the management of refractory disease. It is an exciting time for PMR, and this review aims to explore the recent advancements in both diagnosis and management, while also providing an updated perspective on the relationship between PMR and GCA.

show abstract